aurovalsart hct 160 mg + 25 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - valsartanum + hydrochlorothiazidum - tabletki powlekane - 160 mg + 25 mg
coripren 10 mg + 10 mg tabletki powlekane
recordati ireland limited - lercanidipini hydrochloridum + enalaprili maleas - tabletki powlekane - 10 mg + 10 mg
coripren 20 mg + 20 mg tabletki powlekane
recordati ireland limited - enalaprili maleas + lercanidipini hydrochloridum - tabletki powlekane - 20 mg + 20 mg
aurovalsart hct 320 mg + 12,5 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - valsartanum + hydrochlorothiazidum - tabletki powlekane - 320 mg + 12,5 mg
lorviqua
pfizer europe ma eeig - lorlatinib - rak, niedrobnokomórkowe płuca - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
telmisartan aurovitas 80 mg tabletki
aurovitas pharma polska sp. z o.o. - telmisartanum - tabletki - 80 mg
telmisartan aurovitas 40 mg tabletki
aurovitas pharma polska sp. z o.o. - telmisartanum - tabletki - 40 mg
casaro 16 mg tabletki
medreg s.r.o. - candesartanum cilexetili - tabletki - 16 mg
casaro 8 mg tabletki
medreg s.r.o. - candesartanum cilexetili - tabletki - 8 mg
casaro 32 mg tabletki
medreg s.r.o. - candesartanum cilexetili - tabletki - 32 mg